Company: BFRG
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001641172-25-009946
Chunk: 4

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 1
Chunk 4
---
 Inc. and Bullfrog AI Management, LLC, which were incorporated
in Delaware and Maryland, in 2017 and 2021, respectively. All the Company’s operations are currently conducted through Bullfrog
AI Holdings, Inc., which began operations on February 6, 2020. The Company is focused specifically on advanced artificial intelligence
and machine learning (“AI/ML”) driven analysis of complex data sets in medicine and healthcare. The Company’s objective
is to utilize its AI/ML platform to provide a precision medicine approach to drug asset enablement through external partnerships and
selective internal development.

Most
new therapeutics will fail at some point in preclinical or clinical development. These failures are the primary drivers for the high
cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex
and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial
intelligence and machine learning has emerged as a digital solution to help address this problem.

The
Company uses AI/ML to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their
ability to synthesize disparate, high-dimensional data for actionable insight. The Company’s analytical platform is composed of
an ensemble of state-of-the-art machine learning and artificial intelligence models. The Company’s core platform technology, named
bfLEAP™, is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”),
which the Company believes is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians
by providing a more precise, multi-dimensional understanding of their data. The Company is deploying its analytical platform, including
bfLEAP™, for use in several critical stages of development of internal programs and through strategic partnerships and collaborations
with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing
failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

The
proprietary analytical platform utilizes both supervised and unsupervised machine learning. As such, it is able to reveal real and meaningful
connections in the data without the need for a priori hypothesis. Algorithms used in the platform are designed to handle highly imbalanced
data sets and successfully identify combinations of factors that are associated with outcomes of interest. The Company’s platform
leverages models that use both correlative and caus